The current study aims to assess the prognostic significance of EarlyR using a cohort of patients from the randomized, controlled BIG 1–98 clinical trial of endocrine therapy for postmenopausal women with hormone receptor–positive early breast cancer (12). Here, NR4A1 is linked to breast cancer.